Figure 2 | Scientific Reports

Figure 2

From: Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Figure 2The alternative text for this image may have been generated using AI.

Kaplan–Meier curves for progression-free survival in patients with different imaging parameters. (a) For patients stratified by SUVmax. (b) For patients stratified by HI. Abbreviations: CI, confidence interval; PFS, progression-free survival. SUVmax, maximum standard uptake value. HI, heterogeneity index.

Back to article page